The Institute of Chemical Technology, Mumbai, in collaboration with the Mumbai Biocluster, successfully hosted the 5th Annual ...

Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...

In a report released on February 5, Charles Weston from RBC Capital maintained a Buy rating on Sartorius Stedim Biotech (0RG8 – Research ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...

Sartorius Stedim Biotech SA (SDMHF) reports steady revenue growth and robust order intake, while addressing market pressures ...

Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the Preliminary Results 2024 Conference Call and Live Webcast. I am Yousef, the Chorus Call operator.

Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025. "Business development in ...

(RTTNews) - After opening notably higher, German stocks have pared some gains Tuesday morning as investors are a bit cautious ahead of policy announcements from major central banks, including the ...

(RTTNews) - Sartorius Stedim Biotech reported preliminary fiscal 2024 net profit of 175.1 million euros, down 43.6% from last year. Earnings per share was 1.81 euros compared to 3.37 euros.

Underlying EBITDA and order intake beat should support Sartorius shares and those of its French subsidiary Sartorius Stedim Biotech on Tuesday, J.P.Morgan said in a note to clients. Shares in ...

In a challenging environment, Sartorius Stedim Biotech, a leading provider of innovative technologies for the manufacture of biologics, closed the fiscal year with a solid performance. With sales ...